Intrommune Therapeutics

Private

New York City, New YorkHealthcare & Life Scienceshttps://intrommune.com/

Last Round

Series A

Jun 9, 2021

Est. Valuation

$15.11M

Total Funding Raised

$5.51M

Company Overview

Intrommune Therapeutics is a biotechnology company that is developing a treatment platform for food allergies using oral mucosal immunotherapy (OMIT) delivered through a specially formulated toothpaste.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

oral mucosal immunotherapyOMITfood allergy treatmentpeanut allergy treatmentallergy toothpasteimmunotherapydrug delivery platformallergy desensitizationtoothpaste delivery systemclinical-stage biotechdirect-to-consumer advertising

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Intrommune Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Intrommune Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Jun 9, 2021
Crowdfunding	Apr 12, 2018

View all Funding Rounds

Key People

Founding team and executive leadership

Michael Nelson

Founder & CEO

Founding Team

Intrommune Therapeutics Investors

Notable investors and investment history

Investor	Rounds
Chemical Angel Network	Series A
Robin Hood Ventures	Series A
Red Bear Ventures	Series A
Timberline Holdings	Series A
Netcapital	Crowdfunding

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 20, 2026
Monthly visitors increased 46% MoM.
Nov 6, 2025
Monthly visitors increased 34% MoM.

View all signals

Intrommune Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Intrommune Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Intrommune Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York

Employee Range14

Year Founded2015

Last FundingJun 9, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.